KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Vitamin Profile of the Patients with Chronic Kidney Disease Receiving a Novel Total Parenteral Nutrition Formula: Multicenter Randomized Controlled Phase III Trial.

Ken Tsuchiya, Tatsukuni Kawakami, Yusuke Maniwa, Yoshiyuki Kawauchi, Motofusa Katayama

Ann Nutr Metab 82(1) 36-50

PMID40906605
PMCIDPMC12503829
DOI10.1159/000547656
发表日期2025-09-04
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:AI 判定为 flow diagram;Fig. 2.:AI 判定为 flow diagram;Fig. 3.:AI 判定为 other。
摘要

摘要

UNLABELLED: <p>Introduction: Efficacy and safety of a novel total parenteral nutrition formula for chronic kidney disease patients, OPF-109, containing multivitamins based on the FDA2000 recommendation were investigated. METHODS: We conducted a phase III clinical trial administering OPF-109 (n = 63) or the control solutions (combination of marketed products including multivitamin based on American Medical Association 1975 guidelines) (n = 61) to the chronic kidney disease patients for 8 days. Blood concentrations of proteins and vitamins and safety were evaluated. The primary efficacy endpoint was protein concentration (serum T-P, ALB, pre-ALB, transferrin) on day 8. Safety endpoints were hematological data, blood biochemistry data, vital signs, and adverse events. RESULTS: Values of blood protein until day 8 were similar in 2 groups although those of vitamins B1, B6, C, and folic acid (contained more in OPF-109) were higher in the OPF-109 group. For both groups, vitamin C concentration of day 1 was below the normal range, which restored to within the range in the OPF-109 group but decreased in the control group on day 8. Vitamin K concentration (contained less in OPF-109) was over the normal range on day 1 in both groups and decreased to slightly higher than the normal range in the OPF-109 group while increased to higher than day 1 value in the control group on day 8. Safety was similar in 2 groups. CONCLUSION: Efficacy and safety of OPF-109 and usefulness of multivitamins based on the FDA2000 recommendation formula were confirmed in chronic kidney disease patients. </p>.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1. Study schedule. The OPF-109 group was administrated test solution, and the control group was administrated control solutions. RBW, reference body weight; HRF, HICALIQ™ RF Infusion; KD, KIDMIN ® Injection; OMV, Otsuka MV injection.
非 KM Figure
Fig. 2.Fig. 2. Flowchart of study in which 130 patients were enrolled and then randomized to the intervention. One patient of the control group who completed the trial was excluded from the statistical analysis group due to GCP violation. As a result, efficacy endpoints and safety parameters were assessed in 123 patients (OPF-109 group: 63, control group: 60).
非 KM Figure
Fig. 3.Fig. 3. Blood concentrations of VB1 ( a ), B6 ( b ), C ( c ), folic acid ( d ), and VK ( e ) on day 1, day 5, and day 8. The mean and SD are shown. NR: VB1, 24–66 ng/mL; VB6, male: 6.0–40.0 ng/mL/female: 4.0–19.0 ng/mL; VC, 5.5–16.8 μg/mL, folic acid, ≥4 ng/mL; VK, 0.15–1.25 ng/mL. *: p < 0.05 versus control by Student’s t test.
非 KM Figure